Health & Environmental Research Online (HERO)


Print Feedback Export to File
523559 
Journal Article 
Rimonabant hydrochloride - Antiobesity drug aid to smoking cessation treatment of alcohol dependency cannabinoid CB1 antagonist 
Sorbera, LA; Castaner, J; Silvestre, JS 
2005 
0 
Drugs of the Future
ISSN: 0377-8282 
30 
2 
128-137 
English 
Obese patients are at a higher risk for coronary artery disease, hypertension, hyperlipidemia and diabetes mellitus, among other diseases, and thus their risk of morbidity and mortality increases. Due to the many complex pathophysiological components which lead to obesity, the disease remains a challenging and significant clinical problem. Cannabinoids acting via cannabinoid receptors stimulate food intake and a particularly attractive antiobesity target is the cannabinoid CB, receptor, which has also been shown to play a role in reinforcing reward. Rimonabant hydrochloride (SR-141716A) is a promising CB1 receptor antagonist that was shown to inhibit motivational and consummatory aspects of feeding, as well as alcohol and nicotine intake in animal models. The agent exhibited efficacy in phase III trials as a treatment for obesity and for smoking cessation. Phase II studies are also under way for the treatment of alcoholism. 
SR-141716A; Acomplia(TM); receptor antagonist; food-intake; selective antagonist; inverse; agonism; preferring rats; high-fat; obesity; sr141716a; sr-141716; nicotine